Feuchtbaum Lisa, Lorey Fred, Faulkner Lisa, Sherwin John, Currier Robert, Bhandal Ajit, Cunningham George
Genetic Disease Branch, California Department of Health Services, Richmond, CA 94804, USA.
Pediatrics. 2006 May;117(5 Pt 2):S261-9. doi: 10.1542/peds.2005-2633E.
In response to a California legislative mandate, a pilot tandem mass spectrometry (MS/MS) screening program was undertaken by the Genetic Disease Branch of the California Department of Health Services between January 2002 and June 2003. This article outlines the Genetic Disease Branch approach to implementing the MS/MS pilot program and the program evaluation strategies used.
Through the use of multiple data collection methods, we were able to describe hospital participation patterns, screening test uptake, screening test performance, follow-up services utilization, and provider and family satisfaction with the educational materials and follow-up services provided.
During the 18-month pilot program, just more than one half of California's 755,698 newborns were offered MS/MS screening; among this group, 90% of parents chose to have their newborns screened. Fifty-one newborns were identified with MS/MS-detectable disorders, among 461 patients referred for follow-up testing (0.13% of the screened population). One disorder was diagnosed successfully for every 6939 newborns screened and for every 9 infants referred (excluding phenylketonuria). The overall California population prevalence of MS/MS-detectable disorders was 1 case per 6500 infants (excluding phenylketonuria). The positive predictive value for medium-chain acyl-CoA dehydrogenase deficiency was 86.7%, whereas the positive predictive value for short-chain acyl-CoA dehydrogenase deficiency was 21.6%. For a sample from Hawaii, 1 isovaleric aciduria case was detected among 6132 newborns.
Evaluation of the California MS/MS screening pilot program demonstrated that this technology was effective in identifying additional metabolic disorders. The positive predictive value of screening was particularly good for medium-chain acyl-CoA dehydrogenase deficiency. Overall, patient referral rates were very acceptable. The utility of the program was also demonstrated by positive reviews from patients and providers.
为响应加利福尼亚州的一项立法要求,加利福尼亚州卫生服务部遗传疾病分部于2002年1月至2003年6月开展了一项串联质谱(MS/MS)筛查试点项目。本文概述了遗传疾病分部实施MS/MS试点项目的方法以及所采用的项目评估策略。
通过使用多种数据收集方法,我们得以描述医院参与模式、筛查检测接受情况、筛查检测性能、后续服务利用情况以及提供者和家庭对所提供的教育材料和后续服务的满意度。
在为期18个月的试点项目期间,加利福尼亚州755,698名新生儿中仅有略多于一半的新生儿接受了MS/MS筛查;在这一群体中,90%的父母选择让其新生儿接受筛查。在被转介进行后续检测的461名患者中,有51名新生儿被确诊患有MS/MS可检测出的疾病(占筛查人群的0.13%)。每筛查6939名新生儿以及每转介9名婴儿(不包括苯丙酮尿症)就有1例疾病被成功诊断。加利福尼亚州总体人群中MS/MS可检测出的疾病患病率为每6500名婴儿中有1例(不包括苯丙酮尿症)。中链酰基辅酶A脱氢酶缺乏症的阳性预测值为86.7%,而短链酰基辅酶A脱氢酶缺乏症的阳性预测值为21.6%。在来自夏威夷的一个样本中,在6132名新生儿中检测出1例异戊酸血症病例。
对加利福尼亚州MS/MS筛查试点项目的评估表明,这项技术在识别更多代谢紊乱疾病方面是有效的。筛查的阳性预测值对于中链酰基辅酶A脱氢酶缺乏症尤为良好。总体而言,患者转介率非常令人满意。患者和提供者的积极评价也证明了该项目的效用。